Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$10.60 - $38.12
Next Earnings Date
May 08 2025
Next Earnings Date
May 08 2025
Latest price
Market Cap | $1.56B |
EV | $1.09B |
Shares Outstanding | 112.13M |
Beta | 0.33 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $42.78 |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | - |
EPS | -8.40% |
Operating Cash Flow | -48.20% |
Free Cash Flow | -47.80% |
Revenue | - |
EPS | -9.20% |
Operating Cash Flow | -27.50% |
Free Cash Flow | -29.00% |
Gross Margin 2025E | - |
Net Profit Margin 2025E | - |
ROE 2025E | -33.72% |
ROCE 2024 | -34.40% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Edgewise Therapeutics, Inc.
EWTX
Sector
Healthcare
Industry
Biotechnology
CEO
Koch, Kevin
Employees
110
Website
www.edgewisetx.comIPO Date
2021-03-26
Headquarters
1715 38th Street, Boulder, Colorado, 80301, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved